Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3052W HIGH $7.56
Volume
4.12 M
Value Traded
15.06 M
Short % Float
0.05%
Days to Cover
1.1
-0.55%Week
+18.18%1 Month
-38.31%3 Month
-2.15%6 Month
-83.21%5 Year
-82.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
379.98 M
EPS (TTM)
-1.92
P/E Ratio
-
Ent. Value
682.26 M
Total Shares
104.39 M
Float Shares
91.29 M
Insiders
0.09%
Institutions
0.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
RVNC Catalyst Timeline
Dated clinical, regulatory and corporate events for Revance Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How RVNC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-10-15 | DaxibotulinumtoxinA for Injection (later DAXXIFY) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
17
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DaxibotulinumtoxinA Monoclonal antibodyNot countedNCT03617367 | Cervical Dystonia | Phase 3 | COMPLETED | 658 | May 25, 2021 | ||||||
| DaxibotulinumtoxinA Monoclonal antibodyNot countedNCT03911102 | Lateral Canthal Lines | Phase 2 | COMPLETED | 63 | Apr 23, 2020 | ||||||
| DaxibotulinumtoxinA Monoclonal antibodyNot countedNCT03786770 | Frown Lines | Phase 2 | COMPLETED | 61 | Mar 9, 2020 | ||||||
| DaxibotulinumtoxinA Monoclonal antibodyNot countedNCT02706795 | Torticollis (Spasmodic) | Phase 2 | COMPLETED | 37 | Jul 17, 2017 | ||||||
| DAXXIFY Small moleculeNot countedNCT06411002 | Glabellar Frown Lines | Phase 2 | COMPLETED | 27 | Feb 12, 2025 | ||||||
| DaxibotulinumtoxinA Small moleculeNot countedNCT04259086 | Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) | Phase 2 | COMPLETED | 48 | Nov 2, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every RVNC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DaxibotulinumtoxinA for Injection | Cervical Dystonia | Phase 3 | 2020-10-14 | 125 Unit change from baseline: 12.7; 250 Unit change from baseline: 10.9; placebo change from baseline: 4.3; p value 125 Unit: <0.0001; p value 250 Unit: 0.0006; median duration 125 Unit: 24; median duration 250 Unit: 20.3Read More | Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia - Trial met primary and all secondary endpoints for both 125- and 250-Unit doses with high statisticalRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hollander DavidOfficer (CMO & Global Therapeutics Lead) | Sell | -3,908 104,945 held | $4.17 | 11/18/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in RVNC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.9 % (800 %) | 12.97 M | 2.50 M | 525% ( 2.10 M) |
Ownership Trends
RVNC Short Interest
Shares sold short, counted twice a month.
0.05%
Short % of Float
of tradable shares sold short
3.8M
Shares Sold Short
-14.8% vs prior count
1.1 Low
Days to Cover
trading days of normal volume to buy every short share back
3.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RVNC ranks across every disease it competes in
Competitive Position is a premium feature
See how RVNC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRVNC News
About Revance Therapeutics, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next RVNC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime